Chennai Journal

Necrotizing Enterocolitis Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook

 Breaking News
  • No posts were found

Necrotizing Enterocolitis Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook

April 24
10:05 2023
Necrotizing Enterocolitis Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Necrotizing Enterocolitis pipeline constitutes 4+ key companies continuously working towards developing 4+ Necrotizing Enterocolitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Necrotizing Enterocolitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Necrotizing Enterocolitis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Necrotizing Enterocolitis Market.


Some of the key takeaways from the Necrotizing Enterocolitis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Necrotizing Enterocolitis treatment therapies with a considerable amount of success over the years. 
  • Necrotizing Enterocolitis companies working in the treatment market are EC Evolve Biosystems, Siolta Therapeutics, Noveome Biotherapeutics, Micregen Ltd, Infant Bacterial Therapeutics, and others, are developing therapies for the Necrotizing Enterocolitis treatment 
  • Emerging Necrotizing Enterocolitis therapies such as – Research Programme, STMC-106, ST266, MRG1061, IBP-9414, and others are expected to have a significant impact on the Necrotizing Enterocolitis market in the coming years.   
  • In January 2023, Infant Bacterial Therapeutics’ (IBT) publishes clinical findings in the British Journal of Gastroenterology on the convincing association of clinical events to the feeding primary endpoint of the ‘Connection Study’
  • In January 2022, Infant Bacterial Therapeutics AB announced that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBP9414 is currently in Phase III development for the prevention of necrotizing enterocolitis (NEC) and improvement of feeding tolerance in preterm infants


Necrotizing Enterocolitis Overview

Necrotizing enterocolitis (NEC) is a devastating disease that affects mostly the intestine of premature infants. The wall of the intestine is invaded by bacteria, which cause local infection and inflammation that can ultimately destroy the wall of the bowel (intestine).


Get a Free Sample PDF Report to know more about Necrotizing Enterocolitis Pipeline Therapeutic Assessment-


Emerging Necrotizing Enterocolitis Drugs Under Different Phases of Clinical Development Include:

  • Research Programme: NEC Evolve Biosystems
  • STMC-106: Siolta Therapeutics
  • STP-206: Leadiant Biosciences
  • ST266: Noveome Biotherapeutics
  • MRG1061: Micregen Ltd
  • IBP-9414: Infant Bacterial Therapeutics


Route of Administration

Necrotizing Enterocolitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type


Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type


Necrotizing Enterocolitis Pipeline Therapeutics Assessment

  • Necrotizing Enterocolitis Assessment by Product Type
  • Necrotizing Enterocolitis By Stage and Product Type
  • Necrotizing Enterocolitis Assessment by Route of Administration
  • Necrotizing Enterocolitis By Stage and Route of Administration
  • Necrotizing Enterocolitis Assessment by Molecule Type
  • Necrotizing Enterocolitis by Stage and Molecule Type


DelveInsight’s Necrotizing Enterocolitis Report covers around 4+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Further Necrotizing Enterocolitis product details are provided in the report. Download the Necrotizing Enterocolitis pipeline report to learn more about the emerging Necrotizing Enterocolitis therapies


Some of the key companies in the Necrotizing Enterocolitis Therapeutics Market include:

Key companies developing therapies for Necrotizing Enterocolitis are – Abbott Laboratories, AcelRx Pharmaceuticals, Alexion Pharmaceuticals, Amgen Inc., Avadel Pharmaceuticals, Baxter International Inc., Fresenius Kabi USA, Grifols USA, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceuticals, Teva Pharmaceuticals USA, Thermo Fisher Scientific, United Therapeutics Corporation, Vertex Pharmaceuticals, Zydus Cadila, and others.


Necrotizing Enterocolitis Pipeline Analysis:

The Necrotizing Enterocolitis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Necrotizing Enterocolitis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Necrotizing Enterocolitis Treatment.
  • Necrotizing Enterocolitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Necrotizing Enterocolitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Necrotizing Enterocolitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Necrotizing Enterocolitis drugs and therapies


Necrotizing Enterocolitis Pipeline Market Drivers

  • Increasing contribution towards the research and development activities, improved regulatory framework by the Government towards the development of new antibiotics and therapies are some of the important factors that are fueling the Necrotizing Enterocolitis Market.


Necrotizing Enterocolitis Pipeline Market Barriers

  • However, high cost associated with the treatment, lack of skilled healthcare professionals to carry out the diagnosis and other factors are creating obstacles in the Necrotizing Enterocolitis Market growth.


Scope of Necrotizing Enterocolitis Pipeline Drug Insight    

  • Coverage: Global
  • Key Necrotizing Enterocolitis Companies: EC Evolve Biosystems, Siolta Therapeutics, Noveome Biotherapeutics, Micregen Ltd, Infant Bacterial Therapeutics, and others
  • Key Necrotizing Enterocolitis Therapies: Research Programme, STMC-106, ST266, MRG1061, IBP-9414, and others
  • Necrotizing Enterocolitis Therapeutic Assessment: Necrotizing Enterocolitis current marketed and Necrotizing Enterocolitis emerging therapies
  • Necrotizing Enterocolitis Market Dynamics: Necrotizing Enterocolitis market drivers and Necrotizing Enterocolitis market barriers 


Request for Sample PDF Report for Necrotizing Enterocolitis Pipeline Assessment and clinical trials


Table of Contents


Necrotizing Enterocolitis Report Introduction


Necrotizing Enterocolitis Executive Summary


Necrotizing Enterocolitis Overview


Necrotizing Enterocolitis- Analytical Perspective In-depth Commercial Assessment


Necrotizing Enterocolitis Pipeline Therapeutics


Necrotizing Enterocolitis Late Stage Products (Phase II/III)


Necrotizing Enterocolitis Mid Stage Products (Phase II)


Necrotizing Enterocolitis Early Stage Products (Phase I)


Necrotizing Enterocolitis Preclinical Stage Products


Necrotizing Enterocolitis Therapeutics Assessment


Necrotizing Enterocolitis Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


Necrotizing Enterocolitis Key Companies


Necrotizing Enterocolitis Key Products


Necrotizing Enterocolitis Unmet Needs


Necrotizing Enterocolitis Market Drivers and Barriers


Necrotizing Enterocolitis Future Perspectives and Conclusion


Necrotizing Enterocolitis Analyst Views




About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.


About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States